Rainbow Seed Fund Invests in AgPlus Diagnostics
AgPlus’ handheld electrochemical reader to deliver the next generation of rapid diagnostics Rainbow Seed Fund,…read more
Andrew joined Midven in 2004. He is a Director of the Company and Fund Principal of the Rainbow Seed Fund and the Early Advantage fund.
After an initial scientific career at Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then Vice President of Technology for a US start-up in disinfection of medical equipment.
He started his career in VC with the £4m per annum Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). He has a degree and a PhD in Chemistry from the University of Oxford.
Andrew combines a strong scientific and technical grounding with a real commercial pragmatism developed from his operational roles.
Telephone 0121 710 1990
“Development and commercialisation of new technologies is key to the UK retaining its global competitiveness.”
Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…read more
Midven’s Rainbow Seed Fund, along with SynbiCITE, a pioneering Innovation and Knowledge Centre (IKC), have…read more